• Mashup Score: 0

    On October 9, HistoSonics, the manufacturer of the Edison System and novel histotripsy therapy platforms, announced the marketing authorization of its platform via the U.S. Food and Drug Administration’s (FDA) De Novo Classification Request process, a rigorous premarket review pathway for medical devices with no existing predicate. The Edison System is indicated for the noninvasive destruction of liver tumors, including unresectable liver tumors, using a nonthermal, mechanical process of focused ultrasound

    Tweet Tweets with this article
    • .@US_FDA Authorizes Novel Liver Cancer Treatment https://t.co/wECWLFpOYJ #hpbcsm #livercancer @FDAOncology

  • Mashup Score: 0

    The HER2-targeting bispecific antibody zanidatamab generated rapid and durable responses in patients with HER2-amplified, locally advanced, unresectable or metastatic biliary tract cancer previously treated with gemcitabine, investigators from the global phase IIb HERIZON-BTC-01 study reported at the 2023 ASCO Annual Meeting. 1 The findings were simultaneously published in The Lancet Oncology. 2 HER2 is overexpressed or amplified in a subset of biliary tract cancer, and zanidatamab simultaneously targets

    Tweet Tweets with this article
    • More on Biliary Tract Cancer From ASCO 2023: Focus on Zanidatamab https://t.co/tnwvXLcfZp #hpbcsm #biliarytractcancer #ASCO23 #oncology

  • Mashup Score: 0

    The phase 2 ACTION trial, which evaluated the safety of second-line cabozantinib in patients with hepatocellular carcinoma who were intolerant to first-line sorafenib or who received agents other than sorafenib in the first line, did not meet its safety futility criteria, allowing the trial to continue.

    Tweet Tweets with this article
    • Cabozantinib Is Safe and Tolerable in Sorafenib-Intolerant HCC @MarcoSanduzzi @idibaps @ILCAnews #ILCA23 #hpbcsm https://t.co/Q3dpdPRmhd